Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine ETT Indices in ASCVD
NCT01562041Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ranolazine in coronary artery disease (CAD), sponsored by Novartis. Started Mar 2012; status: terminated.
02
Drugs
ranolazine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01562041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562041.